Poseida Therapeutics (PSTX) investor relations material

Platform technology and business model

• Focuses on proprietary genetic engineering tools for both ex vivo allogeneic CAR-T and in vivo genetic medicines, leveraging non-viral transposon and Cas-CLOVER gene editing technologies.

• Maintains a vertically integrated manufacturing facility, enabling efficient, cost-effective production with over 100 doses per donor batch and biologic-like COGS.

• Holds significant partnerships with Roche (hematologic malignancies) and Astellas (solid tumors), generating over $400 million in milestone payments in three years.

• Extensive IP estate covers gene editing, cell production, and lipid nanoparticle technologies for flexible application.

Clinical pipeline and data highlights

• Lead program P-BCMA-ALLO1 (multiple myeloma, partnered with Roche) in Phase 1B, showing 91% response rate in high-risk, heavily pretreated patients.

• Demonstrates rapid treatment initiation (within one week of enrollment) and confirmed responses in 3.5 weeks, with no bridging therapy required.

• Safety profile shows no GVHD, DLTs, or severe neurotoxicity, with low rates of CRS and infections, supporting outpatient and community use.

• Cross-trial comparisons indicate favorable efficacy and lower adverse event rates versus approved auto CAR-Ts and bispecifics.

Pipeline expansion and future plans

• Advancing P-BCMA-CD19-ALLO1 (wholly owned) for autoimmune diseases, myeloma, and lymphoma, with INDs planned for 2025.

• Genetic medicine programs include P-KLKB1-101 (hereditary angioedema, gene editing) and P-FVIII-101 (hemophilia A, gene insertion), both using non-viral approaches.

• Factor VIII program shows durable, stable protein expression in preclinical models, with a modulating safety switch for titratable efficacy.

• Plans for clinical data updates on MUC1-C solid tumor program and CD19/CD20 CAR-T in late 2024 and 2025.